Other studies in a mouse model of colorectal cancer suggest that activation of NLRP3 results in increased antitumor immunity (45, 46), and in a thymoma model NLRP3 activation increased activation of CD8+ cells during chemotherapy (47). This evidence concerns the gene NLRP3 and thymoma.